BioSpy’s prostate cancer screening breakthrough runs on Rymedi’s blockchain-enabled clinical diagnostic platform

GREENVILLE, SC / ACCESSWIRE / March 26, 2024 / Rymedi is proud to announce our latest collaboration with BioSpy, He is the developer of Prostate IQ®, the next generation prostate cancer screening test. This new partnership leverages Rymedi’s blockchain-backed, Web3-enabled cutting-edge technology, built on the speed, security, and customizability of the Avalanche blockchain network, to deliver the highest efficiency for prostate cancer testing data. and guarantee security.

Approximately 1 in 8 men will be diagnosed with prostate cancer during his lifetime. However, each man’s risk of prostate cancer varies depending on his age, race/ethnicity, and other factors, according to the American Cancer Society. Prostate IQ™ is a race- and age-specific prostate screening test that uses multiplexed microsampling to test for prostate cancer biomarkers in less than one drop of blood in five minutes. The BioSpy collection device enables painless blood collection in the clinic, home, or workplace in 3 to 4 minutes per patient.

“Prostate cancer is the most prevalent cancer in our country, but it often goes undetected during traditional physical exams,” said Dr. Gregory Pinto, a renowned urologist and surgeon. “However, we now employ an advanced blood test specifically designed to detect this cancer with greater accuracy. Utilizing the Prostate IQ⎮ Test, a highly sensitive microfluidic blood test This can lead to five, eight, or even 10 years of prostate cancer symptoms before they become clinically significant.”

The painless nature of the BioSpy collection device allows individuals to take action to collect a blood sample themselves at home or have it tested by a doctor without fear of the testing process. This facilitates a proactive approach to monitoring and timely intervention.

“Along with the accurate and personalized results that our tests provide, we want both patients and healthcare providers to be confident that their BioSpy results adhere to rigorous security and compliance standards. That’s why we’re excited about our partnership with Rymedi,” said Charlie Valentine. He is his partner managing Pinnacle BioLabs, the parent company of BioSpy.

David Stefanich, co-founder and CEO of Rymedi, said: “Rymedi’s technology is revolutionizing the way we share, record and store data with unparalleled security, and we look forward to working with forward-thinking companies to deliver solutions that improve lives. We are excited about our partnership with BioSpy and are committed to helping patients overcome prostate cancer or prevent it from developing. This is what you do. ”

Rymedi utilizes subnets, which are custom blockchains within the Avalanche network. Avalanche was launched in September 2020 and ushered in a new era of blockchain with near-instantaneous transaction finality. Today, Avalanche supports hundreds of applications, secures billions of dollars in value, and boasts more than 1,800 validators, all while minimizing climate impact.

Rymedi enables life sciences organizations like BioSpy to advance human health by providing cutting-edge patient and population health data management software and effective workflow solutions with the highest levels of security and compliance. We support you. All Prostate IQ® orders, samples, shipments, and results data will now be managed on Rymedi’s platform, built on a proprietary blockchain architecture.

About BioSpy

BioSpy revolutionizes prostate cancer screening with cutting-edge technology. The BioSpy collection device facilitates painless blood collection in the clinic, home, or workplace, taking only 3 to 4 minutes per patient. Samples are stable for up to 72 hours at room temperature, streamlining the transportation process to the laboratory and ensuring accurate results. This innovative test eliminates the need for phlebotomists, centrifugation, and refrigeration, and significantly reduces total processing time by 70% compared to traditional laboratory blood collection. BioSpy’s Prostate IQ™ test establishes itself as the only prostate cancer screening test that recognizes ethnicity in its screening algorithm. Incorporating racial stratification provides an individualized risk assessment based on both genotypic and phenotypic data. The test is also age stratified to protect individuals of all ages. This breakthrough test, which uses multiplexed microsampling, requires just one-fifth of a drop of blood. BioSpy Reference Laboratory uses this minimal sample size to test multiple analytes in a single blood microtainer, providing accurate and personalized results. For more information, please visit www.biospy.com.

About Lymedi

Founded in 2018 as a software-as-a-service (SAAS) company, Rymedi is revolutionizing patient and population health data management software and workflow solutions for diagnostic testing, clinical research, occupational health and screening. The Rymedi blockchain-based platform ensures that data is transferred securely while meeting healthcare compliance standards around the world. Its technology stack leverages blockchain, IoT, and AI to improve the consumer experience and provide access to health and certification records. From patient consent and universal mobile health passes to rapid collection deployment and automated reporting, Rymedi facilitates data access across multiple parties and platforms. The ease of use and efficiency of this robust platform increases the revenue and efficiency of disparate data infrastructures, enabling organizations to improve human health while protecting critical health information. For more information, please visit www.rymedi.com.

About Avalanche
Avalanche is a smart contract platform that scales infinitely and regularly completes transactions within a second. With its new consensus protocol, subnet infrastructure, and HyperSDK toolkit, Web3 developers can easily launch powerful custom blockchain solutions. Build what you want, how you want, on a green blockchain designed for Web3 developers.

Website | Whitepaper | Twitter | Discord | Github | Documents | Telegram | Facebook | LinkedIn | Reddit | YouTube

Media contact:

Christina Lowry
KL Communications
[email protected]

sauce: Remedy